Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy.
Takács
István
I
Eros
N
N
Bene
I
I
Bozsó
F
F
Tordai
L
L
Károlyi
Z
Z
Radványi
G
G
Matolcsy
A
A
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001768:Blister / Q000097:blood / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007150:Immunohistochemistry; D007694:Killer Cells, Natural / Q000378:metabolism / Q000473:pathology; D007866:Leg / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use*; D012008:Recurrence; D000069283:Rituximab; D013684:Telangiectasis / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone